{
    "clinical_study": {
        "@rank": "119403", 
        "acronym": "eTNS for DRE", 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the tolerability and safety of the NeuroSigma eTNS\n      system."
        }, 
        "brief_title": "External Trigeminal Nerve Stimulation for Drug Resistent Epilepsy", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Seizure Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Epilepsy", 
                "Seizures"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study evaluates the safety and tolerability of the NeuroSigma eTNS system for the\n      treatment of drug resistent partial seizures.\n\n      Up to 20 subjects, ages 18 - 75, with partial epilepsy will be enrolled in an acute 4-week\n      tolerability study at Olive View/UCLA Medical Center .......\n\n      Enrolled subjects will be asked to maintain an accurate seizure calendar, and will be seen\n      at the initial visit, then at two and four weeks......."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18-65\n\n          -  Partial onset seizures (complex partial or secondary generalized tonic-clonic)\n\n          -  At least one seizure every three months\n\n          -  No serious or progressive medical or psychiatric illness\n\n          -  At least one complex partial or generalized tonic-clonic seizure in the last three\n             months\n\n          -  MRI or EEG consistent with localization-related or partial epilepsy\n\n          -  Exposure to at least two anti-epileptic drugs at adequate doses\n\n          -  Concurrent use of at least one anti-epileptic drug at adequate doses\n\n          -  No change in anti-epileptic drug dose for at least 30 days prior to study enrollment\n\n        Exclusion Criteria:\n\n          -  Vagus nerve stimulation (VNS)\n\n          -  History of non-epileptic seizures\n\n          -  Inability to maintain accurate seizure calendars (self or caregiver)\n\n          -  Frequent use of benzodiazepines for seizure clusters defined as greater that four\n             times per month\n\n          -  History of facial pain or trigeminal neuralgia\n\n          -  Pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": "NCT01607567", 
            "nct_id": "NCT01978470", 
            "org_study_id": "NS-076014-01"
        }, 
        "intervention": {
            "description": "External stimulation of the trigeminal nerve.", 
            "intervention_name": "External Trigeminal Nerve Stimulation (eTNS)", 
            "intervention_type": "Device", 
            "other_name": "eTNS"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "epilepsy", 
            "drug resistent epilepsy", 
            "partial onset seizures", 
            "trigeminal nerve stimulation", 
            "neuromodulation"
        ], 
        "lastchanged_date": "November 1, 2013", 
        "location": {
            "contact": {
                "email": "pmiller@neurosigma.com", 
                "last_name": "Diana Murray", 
                "phone": "818-364-3104"
            }, 
            "facility": {
                "address": {
                    "city": "Sylmar", 
                    "country": "United States", 
                    "state": "California"
                }, 
                "name": "Olive View/UCLA Medical Center"
            }, 
            "investigator": {
                "last_name": "Lara Schrader, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "External Trigeminal Nerve Stimulation for Epilepsy", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number and percent of subjects with adverse events related to the device at four weeks.", 
            "measure": "Safety of eTNS", 
            "safety_issue": "Yes", 
            "time_frame": "Four weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01978470"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Percentage change in Beck Depression Inventory score at four weeks compared to initial visit.", 
                "measure": "Beck Depression Inventory", 
                "safety_issue": "No", 
                "time_frame": "Four weeks"
            }, 
            {
                "description": "Absolute change in QOLIE-31 (Quality of Life in Epilepsy) Inventory scale and sub-scales at four weeks.", 
                "measure": "Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "Four weeks"
            }, 
            {
                "description": "Absolute and percent change in systolic blood pressure and heart rate at four weeks compared to initial visit.", 
                "measure": "Systolic Blood Pressure and Heart Rate", 
                "safety_issue": "Yes", 
                "time_frame": "Four weeks"
            }, 
            {
                "description": "Number and percentage of subjects with skin irritation > 1 on a standardized scale.", 
                "measure": "Skin Irritation", 
                "safety_issue": "Yes", 
                "time_frame": "Four weeks"
            }
        ], 
        "source": "NeuroSigma, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Olive View-UCLA Education & Research Institute", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "NeuroSigma, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}